Additionally, as noted earlier, there is a risk that there is a rebound in weight. Looking at the failed speculative plays I can pat myself on the back for what actually matters in this game: risk management
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) Sodium-glucose cotransporter 2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin) reduce reabsorption of glucose in kidney tubules
Chronic non-adherence compromises therapeutic effectiveness and may lead to suboptimal glycemic control or weight management outcomes
Because of this, many people find that they get more hungry, and it is harder to keep their blood sugar levels steady
Although this proportion is broadly consistent with that observed during substantial weight loss induced by lifestyle interventions or other obesity management therapies, it is not negligible and warrants careful consideration